JESSICA CLIFFORD: Open Payments
NPI 1326553066 · FORT WAYNE, IN. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,443 in 69 payments from 13 companies in 2025. Trend: 2023 $397 · 2024 $596 · 2025 $1,443
Food & beverage: $1,443
| Company | Payments | Amount |
|---|---|---|
| Madrigal Pharmaceuticals | 26 | $462 |
| Gilead Sciences, Inc. | 10 | $198 |
| ABBVIE INC. | 9 | $169 |
| Phathom Pharmaceuticals, Inc. | 2 | $125 |
| Pharmacosmos Therapeutics Inc. | 1 | $104 |
| GENZYME CORPORATION | 5 | $102 |
| Ardelyx, Inc. | 5 | $83 |
| Ipsen Biopharmaceuticals, Inc | 4 | $66 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $57 |
| Regeneron Healthcare Solutions, Inc. | 1 | $21 |
Products named: REZDIFFRA, LINZESS, VOQUEZNA, DUPIXENT, Livdelzi, MONOFERRIC, IBSRELA, IQIRVO.
Industry payments across IN — which companies pay providers there.
